DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Sfrowasa is a drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in SFROWASA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
A generic version of SFROWASA was approved as mesalamine by PERRIGO ISRAEL on September 17th, 2004.
Pharmacology for SFROWASA
|Drug Class||Aminosalicylate |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Mylan Speciality Lp||SFROWASA||mesalamine||ENEMA;RECTAL||019618-002||Jun 20, 2008||AB||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Country||Patent Number||Estimated Expiration|
|New Zealand||578674||Start Trial|
|European Patent Office||0279093||Start Trial|
|European Patent Office||2107870||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|